Febrile Neutropenia — Part 4: Antifungal Therapy, Central Line Infections & Infection Prevention
Empiric and targeted antifungal therapy for invasive aspergillosis and candidemia, central line-associated bloodstream infections in neutropenic patients, infection prevention measures, and patient and caregiver education.
10. Antifungal Therapy in Febrile Neutropenia
10.1 Empiric Antifungal Therapy
Empiric antifungal therapy is indicated when fever persists after 4–7 days of appropriate broad-spectrum antibacterial therapy in patients with prolonged neutropenia (expected ANC < 500 cells/μL for > 7 days), as invasive fungal infections (IFI) are a major cause of morbidity and mortality in this population.1 2 3
Criteria for Initiating Empiric Antifungal Therapy
| Criterion | Details |
|---|---|
| Persistent fever | Fever persisting or recurring after ≥ 4–7 days of adequate broad-spectrum antibacterial therapy |
| Expected prolonged neutropenia | ANC < 500 cells/μL expected to persist for > 7 additional days |
| No identified bacterial source | Blood cultures and other workup have not identified a clear bacterial cause |
| Clinical suspicion | Particularly if there are new pulmonary infiltrates, sinusitis symptoms, hepatosplenic lesions, or skin lesions suggestive of fungal etiology |
Alternative Approach: Pre-emptive (Diagnostic-Driven) Strategy
Some institutions use a pre-emptive rather than purely empiric approach, reserving antifungal therapy for patients with positive biomarkers or suggestive imaging:3 4
| Component | Details |
|---|---|
| Monitoring | Serial serum galactomannan (twice weekly) and/or serum 1,3-beta-D-glucan during the neutropenic period |
| CT imaging | CT chest performed early (at day 4–7 of persistent fever) to detect pulmonary infiltrates before they become visible on plain radiograph |
| Treatment trigger | Antifungal therapy initiated upon positive galactomannan (index ≥ 0.5 for single sample, or ≥ 0.7 per some institutions), positive beta-D-glucan (≥ 80 pg/mL), or suspicious CT findings (nodules, halo sign) |
| Advantage | Reduces unnecessary antifungal exposure and costs; comparable outcomes to empiric approach in select studies |
| Limitation | Requires reliable and timely biomarker testing; galactomannan sensitivity reduced in patients receiving mold-active antifungal prophylaxis |
10.2 Empiric Antifungal Agent Selection
| Agent | Dose | Route | Coverage | Key Notes |
|---|---|---|---|---|
| Caspofungin | 70 mg IV on day 1 (loading dose), then 50 mg IV daily | IV | Candida species (including most azole-resistant species); Aspergillus (fungistatic, not fungicidal) | Well-tolerated; recommended as empiric antifungal in landmark trial (Walsh et al., NEJM 2004)5; hepatic dose adjustment (50 mg → 35 mg daily for moderate hepatic impairment, Child-Pugh B); minimal drug interactions compared to azoles |
| Micafungin | 100 mg IV once daily | IV | Similar to caspofungin | Alternative echinocandin; no loading dose required; hepatic safety profile generally favorable |
| Anidulafungin | 200 mg IV on day 1, then 100 mg IV daily | IV | Similar to caspofungin | Alternative echinocandin; least hepatic metabolism; may be preferred in patients with significant hepatic dysfunction |
| Liposomal amphotericin B | 3 mg/kg IV once daily | IV | Broadest spectrum: Candida, Aspergillus, Mucorales (Zygomycetes), endemic mycoses, Fusarium | Traditional empiric standard; significant nephrotoxicity risk even with liposomal formulation (less than conventional amphotericin B deoxycholate); infusion-related reactions; premedicate with acetaminophen and diphenhydramine; monitor renal function, potassium, magnesium |
| Voriconazole | 6 mg/kg IV every 12 hours on day 1 (loading), then 4 mg/kg IV every 12 hours; or 200 mg PO every 12 hours | IV or PO | Aspergillus, most Candida species (not C. glabrata in some cases), Fusarium, Scedosporium | Not recommended as first-line empiric therapy in FN (non-inferior to liposomal amphotericin B was not demonstrated in the empiric FN trial); however, first-line for documented invasive aspergillosis; many drug interactions; therapeutic drug monitoring required (target trough 1–5.5 mcg/mL); visual disturbances; hepatotoxicity |
Empiric Antifungal Agent Selection by Clinical Scenario
| Scenario | Recommended Agent(s) |
|---|---|
| Standard empiric therapy for persistent FN | Caspofungin (or other echinocandin) OR liposomal amphotericin B |
| Patient already on fluconazole prophylaxis | Caspofungin, micafungin, or liposomal amphotericin B (need mold-active agent since fluconazole does not cover Aspergillus) |
| Patient already on mold-active prophylaxis (posaconazole, voriconazole) | Liposomal amphotericin B or echinocandin (breakthrough on azole may indicate azole-resistant organism); infectious disease consultation recommended |
| Concern for mucormycosis (Mucorales) | Liposomal amphotericin B (echinocandins and voriconazole have no activity against Mucorales); consider isavuconazole or posaconazole for step-down |
| Renal impairment | Echinocandin preferred (no renal dose adjustment needed); avoid or use caution with liposomal amphotericin B; avoid IV voriconazole (cyclodextrin vehicle accumulates in renal impairment — use oral formulation) |
10.3 Targeted Antifungal Therapy — Invasive Aspergillosis
Invasive pulmonary aspergillosis (IPA) is the most common invasive mold infection in neutropenic patients, particularly those with AML/MDS and allogeneic HSCT recipients. Mortality remains 30–60% despite treatment.3 6
Diagnosis
| Diagnostic Modality | Findings |
|---|---|
| CT chest | Nodules (often peripheral), halo sign (ground-glass opacity surrounding a nodule — early finding), air-crescent sign (late finding indicating cavitation), wedge-shaped infarcts; CT is far superior to chest radiograph for early detection |
| Serum galactomannan (GM) | Optical density index ≥ 0.5 considered positive; sensitivity ~70% in hematologic malignancy patients not on mold-active prophylaxis; reduced sensitivity (< 30%) in patients receiving posaconazole or voriconazole prophylaxis |
| BAL galactomannan | Optical density index ≥ 1.0 considered positive; higher sensitivity than serum GM |
| Serum 1,3-beta-D-glucan | ≥ 80 pg/mL suggests IFI (not specific to Aspergillus — also positive in Candida, Pneumocystis, and other fungi) |
| Tissue biopsy and culture | Gold standard for definitive diagnosis; shows septate, dichotomously branching hyphae at 45° angles on histopathology; culture confirms species |
| Aspergillus PCR | Increasingly available; may complement GM testing; not yet universally standardized |
Treatment of Invasive Aspergillosis
| Line | Agent | Dose | Notes |
|---|---|---|---|
| First-line | Voriconazole | 6 mg/kg IV every 12 hours on day 1, then 4 mg/kg IV every 12 hours; transition to 200–300 mg PO every 12 hours when stable | Standard of care based on landmark randomized trial (Herbrecht et al., NEJM 2002)7; superior to amphotericin B deoxycholate; therapeutic drug monitoring essential (trough 1–5.5 mcg/mL); treat for minimum 6–12 weeks; continue until resolution of lesions and immune reconstitution |
| First-line alternative | Isavuconazole | 200 mg IV or PO every 8 hours for 6 doses (loading), then 200 mg IV or PO once daily | Non-inferior to voriconazole (SECURE trial); fewer hepatic and visual adverse effects; fewer drug interactions than voriconazole; does not require therapeutic drug monitoring (though may be considered); well-tolerated |
| Salvage therapy | Liposomal amphotericin B | 3–5 mg/kg IV once daily | For patients failing or intolerant of voriconazole/isavuconazole |
| Salvage therapy | Posaconazole | 300 mg PO twice on day 1, then 300 mg PO once daily (delayed-release tablets) | Oral salvage option |
| Salvage combination | Voriconazole + echinocandin | Voriconazole at standard doses + caspofungin 70/50 mg IV daily or micafungin 150 mg IV daily | May be considered in refractory disease; limited evidence; use with infectious disease guidance |
10.4 Targeted Antifungal Therapy — Invasive Candidiasis and Candidemia
Candidemia is the most common invasive fungal infection identified by blood culture in neutropenic patients.1 8
Initial Treatment
| Agent | Dose | Notes |
|---|---|---|
| Echinocandin (preferred) | Caspofungin 70 mg IV day 1, then 50 mg IV daily; OR micafungin 100 mg IV daily; OR anidulafungin 200 mg IV day 1, then 100 mg IV daily | Recommended as first-line therapy for candidemia by major guidelines; fungicidal against most Candida species; effective against C. glabrata and C. krusei; well-tolerated |
| Fluconazole (step-down) | 800 mg (12 mg/kg) IV or PO on day 1, then 400 mg (6 mg/kg) IV or PO daily | May be used for step-down therapy after initial echinocandin treatment in patients with susceptible Candida species (e.g., C. albicans, C. parapsilosis) who are clinically stable and have negative repeat blood cultures; not recommended as first-line in critically ill or neutropenic patients |
| Amphotericin B (liposomal) | 3–5 mg/kg IV daily | Alternative for patients intolerant of echinocandins or with echinocandin-resistant Candida; broader spectrum |
Candida Species-Specific Considerations
| Species | Antifungal Notes |
|---|---|
| C. albicans | Generally susceptible to echinocandins and fluconazole; fluconazole step-down appropriate once susceptibility confirmed |
| C. glabrata | Reduced susceptibility to fluconazole (intrinsic dose-dependent susceptibility); echinocandin preferred; perform susceptibility testing |
| C. krusei | Intrinsically resistant to fluconazole; echinocandin preferred |
| C. parapsilosis | Higher echinocandin MICs (though clinical significance debated); fluconazole may be preferred if susceptible; monitor response closely |
| C. auris | Emerging multidrug-resistant species; often resistant to fluconazole; variable echinocandin susceptibility; susceptibility testing essential; infectious disease and infection prevention consultation required; requires contact precautions |
Duration and Monitoring for Candidemia
| Parameter | Recommendation |
|---|---|
| Blood culture clearance | Repeat blood cultures every 24–48 hours until negative |
| Treatment duration | Minimum 14 days after first negative blood culture AND resolution of signs/symptoms AND neutrophil recovery |
| Ophthalmologic examination | Dilated fundoscopic examination to evaluate for Candida endophthalmitis; perform when neutropenia resolves (examination may be unreliable during profound neutropenia) |
| Echocardiography | Consider transthoracic echocardiography to evaluate for endocarditis, particularly in patients with persistent candidemia or prosthetic heart valves |
| Line management | Central venous catheter removal is strongly recommended for non-neutropenic patients with candidemia; in neutropenic patients, catheter removal is recommended when feasible, though the decision may be more complex if the catheter is essential for ongoing chemotherapy and the source of candidemia is uncertain (see Section 11) |
11. Central Line-Associated Infections in Neutropenic Patients
Central venous catheters (CVCs) are essential for chemotherapy administration, blood product transfusion, and supportive care in oncology patients, but they represent a major source of bloodstream infection.1 9
11.1 Types of Catheter-Related Infections
| Type | Definition | Management |
|---|---|---|
| Exit site infection | Erythema, tenderness, induration, or purulence within 2 cm of the catheter exit site, without bloodstream infection | Topical and/or systemic antibiotics based on culture; catheter may be retained if symptoms resolve |
| Tunnel infection | Erythema, tenderness, or induration extending > 2 cm from the exit site along the subcutaneous tunnel of a tunneled catheter | Systemic antibiotics plus catheter removal; tunnel infections rarely resolve without line removal |
| Port pocket infection | Erythema, tenderness, swelling, or purulence over the implanted port reservoir | Systemic antibiotics plus port removal |
| Catheter-related bloodstream infection (CRBSI) | Bacteremia or fungemia with ≥ 1 positive blood culture from a peripheral vein, clinical signs of infection, and no other apparent source; differential time to positivity (CVC culture positive ≥ 2 hours before peripheral culture) supports the diagnosis | Systemic antibiotics; catheter removal based on pathogen and clinical response (see below) |
11.2 Catheter Management Decisions in CRBSI
| Pathogen / Scenario | Catheter Recommendation |
|---|---|
| Staphylococcus aureus | Remove catheter — high rates of metastatic infection, endocarditis, and treatment failure with catheter retention |
| Candida species | Remove catheter — strongly recommended; improved outcomes with early catheter removal |
| Pseudomonas aeruginosa | Remove catheter — high rate of treatment failure with line retention |
| Mycobacterium species | Remove catheter |
| Bacillus species | Remove catheter |
| Coagulase-negative staphylococci | Catheter may be retained with antibiotic lock therapy + systemic antibiotics if: the catheter is functional, the patient is clinically stable, blood cultures clear within 72 hours; remove if persistent bacteremia or clinical deterioration |
| Enterococcus species | Consider catheter removal, especially if bacteremia persists > 72 hours despite appropriate antibiotics |
| Gram-negative bacilli (other than Pseudomonas) | Attempt catheter salvage with systemic antibiotics ± antibiotic lock therapy; remove if bloodstream infection persists > 72 hours |
11.3 Antibiotic Lock Therapy
Antibiotic lock therapy (ALT) involves instilling a concentrated antibiotic solution into the catheter lumen and allowing it to dwell for several hours (typically 8–24 hours per day, alternating with periods of catheter use). ALT may be used as adjunctive therapy when attempting catheter salvage.9
| Agent | Concentration (typical) | Notes |
|---|---|---|
| Vancomycin lock | 2–5 mg/mL | For gram-positive CRBSI when catheter salvage is attempted |
| Daptomycin lock | 5 mg/mL | Alternative for gram-positive organisms |
| Gentamicin lock | 1–2 mg/mL | For gram-negative CRBSI |
| Ethanol lock | 70% | Used as adjunctive therapy in some institutions; broadly antimicrobial; may damage certain catheter materials — check compatibility |
- ALT is used in addition to systemic antibiotics, not as a substitute.
- ALT duration: typically 7–14 days, concurrent with systemic antibiotic therapy.
- ALT is not appropriate for tunnel infections, port pocket infections, or septic thrombophlebitis.
12. Infection Prevention Measures
Infection prevention is a critical component of care for neutropenic patients. Strategies aim to reduce exposure to potential pathogens during the vulnerable period of immunosuppression.1 10
12.1 Standard and Transmission-Based Precautions
| Measure | Details |
|---|---|
| Hand hygiene | The single most important infection prevention measure; all healthcare workers, patients, and visitors must perform hand hygiene with alcohol-based hand rub or soap and water before and after patient contact |
| Standard precautions | Apply to all patient encounters; include hand hygiene, use of personal protective equipment (PPE) for anticipated exposure to blood/body fluids, safe injection practices, and respiratory hygiene |
| Contact precautions | Implement for patients colonized or infected with multidrug-resistant organisms (MRSA, VRE, ESBL-producing organisms, CRE, C. auris) |
| Droplet/airborne precautions | Implement for respiratory infections (influenza, COVID-19, tuberculosis, varicella) per standard protocols |
12.2 Environmental Measures
| Measure | Details |
|---|---|
| Private room | Preferred for all neutropenic patients; required for allogeneic HSCT recipients |
| Protective environment (PE) | Recommended for allogeneic HSCT recipients: HEPA-filtered air (≥ 12 air changes per hour), positive pressure relative to corridor, well-sealed rooms, directed airflow; not routinely required for patients undergoing standard chemotherapy |
| Construction precautions | If hospital construction is occurring near neutropenic patient care areas, implement dust-containment measures and enhanced air quality monitoring (construction activity aerosolizes Aspergillus spores) |
| Water safety | Avoid exposing neutropenic patients to stagnant water; ensure hospital water systems are managed to minimize Legionella and other waterborne pathogens |
| Plants and flowers | Fresh flowers and potted plants should not be permitted in rooms of severely neutropenic patients (potential source of Aspergillus and gram-negative organisms) |
12.3 Dietary Recommendations (Neutropenic Diet)
The traditional “neutropenic diet” (avoiding fresh fruits, vegetables, and other raw foods) has been a longstanding practice, but evidence supporting its efficacy is limited. Current guidance has shifted toward a food safety approach rather than a restrictive neutropenic diet.1 10
| Recommendation | Details |
|---|---|
| General food safety | Wash hands before preparing and eating food; wash all fresh fruits and vegetables thoroughly; cook meats, poultry, fish, and eggs to safe internal temperatures |
| Avoid | Raw or undercooked meat, poultry, seafood, or eggs; unpasteurized dairy products and juices; soft cheeses made from unpasteurized milk; raw sprouts; well water (unless treated) |
| Fresh produce | Washed fresh fruits and vegetables are generally considered safe; thick-skinned fruits that can be peeled (bananas, oranges) are acceptable |
| Tap water | Generally considered safe in municipal water systems in developed countries; if immunocompromised patients are concerned, boiled or filtered water may be used |
| Probiotics | Live culture supplements and probiotic-containing foods are not recommended for severely neutropenic patients due to rare reports of bacteremia and fungemia with probiotic organisms |
12.4 Additional Infection Prevention Measures
| Measure | Details |
|---|---|
| Visitor restrictions | Visitors with active respiratory infections, fever, or contagious illnesses should not visit; limit the number of visitors during profound neutropenia |
| Avoiding crowds | Patients should avoid crowded places during periods of neutropenia |
| Dental care | Dental evaluation and any necessary dental work should be completed before initiating myelosuppressive chemotherapy; during neutropenia, avoid dental procedures |
| Pet exposure | Avoid contact with pet feces, aquariums, reptiles, and birds; hand hygiene after contact with household pets |
| Skin and catheter care | Daily inspection of central line sites; sterile dressing changes per institutional protocol (typically every 7 days for transparent dressings, every 2 days for gauze); daily bathing with chlorhexidine gluconate (CHG) wipes or solution may reduce skin colonization |
| Influenza vaccination | Annual influenza vaccination is recommended for all cancer patients (ideally between chemotherapy cycles when immune response may be better); inactivated vaccine only — live attenuated nasal spray is contraindicated |
| COVID-19 vaccination | Follow current vaccination guidance for immunocompromised patients; timing relative to chemotherapy may affect immune response |
| Pneumococcal vaccination | Per immunocompromised patient vaccination schedule |
13. Patient and Caregiver Education
Effective patient and caregiver education is essential for early recognition of febrile neutropenia, appropriate self-monitoring, and timely presentation for medical care.1 2
13.1 Education Topics
All patients starting myelosuppressive chemotherapy should receive education on the following topics before the first cycle:1
| Topic | Key Messages |
|---|---|
| What is neutropenia | Explanation that chemotherapy lowers white blood cell counts, making patients vulnerable to infections; neutropenia typically occurs 7–14 days after chemotherapy (varies by regimen) |
| Fever monitoring | Take oral temperature whenever feeling unwell, warm, or having chills; know the threshold: a single temperature ≥ 38.3 °C (101.0 °F) or a sustained temperature ≥ 38.0 °C (100.4 °F) for 1 hour is a medical emergency |
| When to call immediately | Fever ≥ 38.3 °C, rigors/chills, new cough or shortness of breath, mouth sores or difficulty swallowing, abdominal pain or diarrhea, burning with urination, redness/swelling/drainage at catheter site or any wound, new skin rash or lesions, confusion or altered mental status |
| When to go to the emergency department | Fever ≥ 38.3 °C if unable to reach the oncology team within 30 minutes; any signs of sepsis (high heart rate, low blood pressure, confusion); rigors; severe symptoms |
| Medications to avoid | Do not take acetaminophen (paracetamol) or ibuprofen to lower fever before calling the oncology team — these may mask fever; follow the specific guidance of the oncology team regarding antipyretic use |
| Infection prevention at home | Hand hygiene; food safety; avoid sick contacts; avoid gardening in soil without gloves; daily shower or bath; oral care |
| Central line care | Keep dressing clean and dry; do not submerge the line site in water; report any redness, swelling, pain, or drainage at the site |
| G-CSF injection technique | If self-administering filgrastim: proper injection technique, storage requirements (refrigerated), disposal of sharps |
13.2 Written Materials and Emergency Plan
- Provide a written emergency card with:
- Patient name and diagnosis
- Oncologist name and emergency contact number (24/7)
- Definition of fever (≥ 38.3 °C or ≥ 100.4 °F sustained)
- Instructions to present to the emergency department immediately if fever occurs during expected neutropenia
- Current chemotherapy regimen and date of last treatment
- Current medications including prophylactic antibiotics
- Note to the ED: “This patient is receiving chemotherapy and may be neutropenic. Febrile neutropenia is a medical emergency. Please check CBC and blood cultures and initiate empiric broad-spectrum antibiotics within 60 minutes of arrival.”
13.3 Communication with Emergency Departments
Institutions should establish protocols ensuring that when a neutropenic oncology patient presents to the emergency department:1
- Triage protocols flag patients with a history of recent chemotherapy and fever for immediate assessment.
- Standing order sets for FN workup (blood cultures, CBC, CMP, lactate) and empiric antibiotics are available.
- Communication pathways between the emergency department and the oncology team are clearly defined.
- A goal of door-to-antibiotic time of ≤ 60 minutes is established and monitored as a quality metric.
14. Summary of Key Recommendations
| Domain | Key Recommendation |
|---|---|
| Definition | Fever ≥ 38.3 °C (single) or ≥ 38.0 °C (sustained ≥ 1 hour) with ANC < 500 cells/μL or < 1,000 cells/μL and predicted decline |
| Risk stratification | Use MASCC score (≥ 21 = low risk) ± CISNE score (0 = low risk) to guide management setting |
| Empiric therapy timing | Broad-spectrum antibiotics within 60 minutes of presentation |
| Empiric monotherapy | Piperacillin-tazobactam 4.5 g IV q6h, cefepime 2 g IV q8h, meropenem 1 g IV q8h, or imipenem-cilastatin 500 mg IV q6h |
| Vancomycin | Add only for specific indications (hemodynamic instability, suspected CRBSI, MRSA risk, severe mucositis, positive gram-positive cultures); discontinue at 48–72 hours if cultures are negative |
| Outpatient management | Low-risk patients meeting all eligibility criteria: ciprofloxacin 500–750 mg PO q12h + amoxicillin-clavulanate 875/125 mg PO q12h with close follow-up |
| Persistent fever | Re-evaluate at day 4–7; CT chest; galactomannan/beta-D-glucan; initiate empiric antifungal therapy (echinocandin or liposomal amphotericin B) |
| G-CSF prophylaxis | Primary prophylaxis when FN risk ≥ 20% (pegfilgrastim 6 mg SC once per cycle or filgrastim 5 mcg/kg/day SC); secondary prophylaxis after prior FN if dose intensity is important |
| Antibacterial prophylaxis | Levofloxacin or ciprofloxacin for patients with expected ANC < 100 cells/μL for > 7 days |
| Antifungal prophylaxis | Posaconazole for AML/MDS induction and allogeneic HSCT with GVHD; fluconazole for candida-risk populations |
| Antibiotic duration | Continue until afebrile ≥ 48 hours AND ANC ≥ 500 cells/μL and rising; tailor to documented infections |
| Catheter management | Remove CVC for S. aureus, Candida, or Pseudomonas bacteremia; consider salvage for coagulase-negative staphylococci |
| Infection prevention | Hand hygiene, food safety, protective environment for HSCT, patient education, vaccination |
References
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America (IDSA). Clin Infect Dis. 2011;52(4):e56-e93. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology (ASCO) and Infectious Diseases Society of America (IDSA) clinical practice guideline update. J Clin Oncol. 2018;36(14):1443-1453. ↩︎ ↩︎
Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118. ↩︎ ↩︎ ↩︎
Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41(9):1242-1250. ↩︎
Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351(14):1391-1402. ↩︎
Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America (IDSA). Clin Infect Dis. 2016;63(4):e1-e60. ↩︎
Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-415. ↩︎
Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America (IDSA). Clin Infect Dis. 2016;62(4):e1-e50. ↩︎
Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America (IDSA). Clin Infect Dis. 2009;49(1):1-45. ↩︎ ↩︎
Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-1238. ↩︎ ↩︎